Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Stefan Feulner on August 5th, 2025 | 07:00 CEST

Xiaomi, Almonty Industries, and BioNTech achieve strategic milestones

  • Mining
  • Tungsten
  • Biotechnology
  • consumergoods

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting the supply of important minerals to Western defense companies, which are needed for everything from ammunition to fighter jets. This development is prompting manufacturers to urgently seek alternative global sources for such critical raw materials to ensure continued production. One producer in particular has come to the forefront in recent weeks, as it can solve the shortage of the essential metal tungsten for the Western world.

Read

Commented by André Will-Laudien on July 30th, 2025 | 07:00 CEST

Trump's Tariffs & Takeovers! BioNTech, PanGenomic Health, Pfizer, and Valneva Targeted by Speculators

  • Healthcare
  • healthtech
  • Biotechnology
  • Pharma

The US-EU tariff agreement has now been finalized. Many sectors of the European economy will now face additional burdens and margin cuts. The biotech and pharmaceutical industries have been spared, as medicines and active pharmaceutical ingredients are among the few product groups that are traditionally traded duty-free in transatlantic trade. This is due to international agreements, such as the WTO Pharmaceutical Agreement, which both the EU and the US have signed. Clinical trial drugs, active ingredient imports, and vaccines are also mostly exempt from tariffs. Valneva is currently making headlines with its chikungunya vaccine, BioNTech and Pfizer are continuing to sell COVID-19 vaccines on a small scale, and PanGenomic is surprising everyone with a new AI-powered health platform. A lot is going on in the sector – who are the big earners?

Read

Commented by Fabian Lorenz on July 24th, 2025 | 07:20 CEST

AI stocks: Buy SAP now? BioNTech surprises! NetraMark beats ChatGPT!

  • Biotechnology
  • Biotech
  • AI

SAP shares performed poorly yesterday. However, the software company is running smoothly and making progress in expanding its AI and cloud business. Is now a good time to get in? Analysts see around 50% upside potential for NetraMark shares. The AI specialist supports Big Pharma in efficient drug development – a billion-dollar market. Now NetraAI has even beaten ChatGPT and DeepSeek! BioNTech is also betting on artificial intelligence. However, the Mainz-based company is currently only making headlines with a change in personnel, but this could change on August 4. Will there be new impetus soon?

Read

Commented by Armin Schulz on July 16th, 2025 | 07:10 CEST

Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution

  • Biotechnology
  • Biotech
  • Healthcare
  • healthtech

The global healthcare system is facing a turning point in 2025. Climate change, chronic diseases, and the scars left by pandemics are challenging existing systems, while digitalization and AI are rapidly advancing new therapies. Governments are investing billions in modern healthcare infrastructure, but debates about data protection and scheduling doctor's appointments are escalating. While the WHO warns of stagnation, groundbreaking alliances between research and industry are emerging. This is precisely where Novo Nordisk, BioNxt Solutions, and BioNTech come in with visionary technologies that not only heal but also open up opportunities for investors.

Read

Commented by André Will-Laudien on July 14th, 2025 | 07:25 CEST

DAX correction! Biotech in takeover mode! BioNTech, CureVac, Pfizer, Vidac Pharma, and Kraft Heinz in focus

  • Biotechnology
  • Biotech
  • Pharma

The stock markets are in top form: both the DAX and the NASDAQ 100 have flexed their muscles in recent days. Prices are being driven primarily by the continued strength of technology stocks and growing hopes for stable global economic growth, despite Donald Trump's tariff madness. At the same time, a growing takeover fever in the biotechnology sector is providing additional momentum. In the field of cancer research in particular, companies such as BioNTech, Moderna, and other specialized mRNA players such as CureVac are increasingly becoming the focus of strategic investors. The fight against cancer is increasingly becoming one of the key drivers for new partnerships and market consolidation. Speculation about possible mergers and billion-dollar acquisitions is currently on the rise again. This opens up an exciting environment for investors, offering opportunities for above-average returns. We identify the trigger points.

Read

Commented by Fabian Lorenz on July 11th, 2025 | 07:20 CEST

Biotech takeover merry-go-round picks up speed! BioNTech, Evotec, Merck, and BioNxt Solutions!

  • Biotechnology
  • Biotech
  • Pharma

The takeover merry-go-round is spinning faster again in the biotech sector. The latest example is Merck's acquisition of Verona Pharma. The US group is paying USD 10 billion for the deal. BioNxt Solutions would be significantly cheaper to acquire at present. The Company aims to make it easier to take medication with melt films, skin patches, and tablets. In addition, it has now announced an exciting platform. The goal is to develop smarter chemotherapy, which, in turn, could create a billion-dollar market. And what are BioNTech and Evotec doing? Things have quieted down a bit at the German biotech leader following its billion-dollar deal with Bristol-Myers Squibb. However, analysts recommend buying the stock. Evotec, on the other hand, is languishing at around EUR 7. Can the quarterly figures provide new impetus for the struggling stock?

Read

Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST

How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns

  • Biotechnology
  • healthtech
  • Biotech
  • AI

Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.

Read

Commented by Nico Popp on July 4th, 2025 | 07:10 CEST

Biotech stocks with a safety net and double bottom: Vidac Pharma, BioNTech, and Gilead Sciences

  • Biotechnology
  • Biotech
  • Pharma

For many years, biotech stocks were considered speculative bets on a single, all-important active ingredient. For seasoned biotech investors, it was once clear that there was little gray area between multiplication and total loss. But the biotech landscape has changed. Innovative technologies and modern processes ensure that even smaller biotech companies have several arrows in their quiver that can hit the mark. We explain what has changed in the biotech sector and what opportunities for collaboration could exist between BioNTech, Gilead Sciences, and Vidac Pharma.

Read

Commented by Mario Hose on July 1st, 2025 | 09:25 CEST

Why Almonty Industries could become the BioNTech of critical metals

  • Mining
  • Tungsten
  • Defense
  • Investments

Between 2019 and 2021, investors in BioNTech witnessed a prime example of how a strategically relevant product – in this case, the COVID-19 vaccine – became a real stock market rocket thanks to government pressure, political support, and high public expectations. During this period, the share price rose from less than EUR 12.00 to over EUR 397.00. Those who invested early and were patient were able to achieve returns of over 3,200%. The decisive driver was not only technological innovation but also the government's determination to have the population vaccinated multiple times, which secured massive revenues for BioNTech. Today, a strikingly similar scenario is emerging with Almonty Industries (WKN: A1JSSD | ISIN: CA0203981034 | Ticker symbol: ALI) – only this time it is not about vaccines, but about the strategic raw material tungsten, which is indispensable for defense, aerospace, electronics, and mechanical engineering.

Read

Commented by Nico Popp on July 1st, 2025 | 07:00 CEST

Disruption! Everything is changing: BioNxt Solutions, BioNTech, Bio-Rad Laboratories

  • Biotechnology
  • Biotech
  • Pharma

The outbreak of the COVID-19 pandemic changed many things. True to the motto "just do it," companies like BioNTech have put their faith in mRNA technology—and within months, success followed, along with billions in revenue. Today, there are once again innovations with the potential to turn small companies into major cash cows. We explain what innovative healthcare companies BioNxt Solutions, BioNTech, and Bio-Rad Laboratories are currently working on and what potential this offers investors.

Read